Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Sevilla

1 657 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sevilla at a glance
1 657
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 657 trials in Sevilla

Open in trial search

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

Major depression

Recruiting

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Colitis ulcerative

Recruiting

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Systemic lupus erythematosus

Recruiting

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Recruiting

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Sevilla

What the registry says about research in the country

01 Metabolic and Endocrine Disorders

Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.

  • Diabetes Management
  • Obesity Treatment
  • Metabolic Disorders

Studies aim to improve treatment outcomes for patients with complex metabolic conditions.

02 Neurological Conditions

Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.

  • Multiple Sclerosis Therapies
  • Neurodegenerative Diseases
  • Brain Health Innovation

Research focuses on developing targeted treatments for various neurological conditions.

03 Infectious Diseases

Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.

  • Vaccine Development
  • Viral Infections
  • Immunization Studies

Studies aim to enhance vaccine efficacy and immune response across different age groups.

04 Oncology Research

Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Therapies
  • Combination Treatments

Focus on developing innovative approaches to improve cancer treatment outcomes.

05 Autoimmune Conditions

Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.

  • Arthritis Treatment
  • Inflammatory Diseases
  • Immune System Disorders

Research aims to develop more effective treatments for chronic autoimmune conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.